700 results match your criteria Prostate Cancer - Neoadjuvant Androgen Deprivation


Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer.

Clin Cancer Res 2022 Jun 13. Epub 2022 Jun 13.

Institute of Cancer Research, Sutton, United Kingdom.

Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker of AR-targeted therapy resistance in castration-resistant prostate cancer (CRPC), but its importance in CSPC remains understudied.

Experimental Design: We assessed different approaches to quantify AR-V7 mRNA and protein in prostate cancer cell lines, patient-derived xenograft (PDX) models, publicly available cohorts, and independent institutional clinical cohorts, to identify reliable approaches for detecting AR-V7 mRNA and protein and its association with clinical outcome. Read More

View Article and Full-Text PDF

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.

Sci Rep 2022 Jun 11;12(1):9675. Epub 2022 Jun 11.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

We aimed to determine the survival and staging benefit of limited pelvic lymph node dissection (PLND) during radical prostatectomy (RP) in high-risk prostate cancer (PC) patients treated with neoadjuvant chemohormonal therapy. We retrospectively analyzed 516 patients with high-risk localized PC (< cT4N0M0) who received neoadjuvant androgen-deprivation therapy plus estramustine phosphate followed by RP between January 2010 and March 2020. Since we stopped limited PLND for such patients in October 2015, we compared the surgical outcomes and biochemical recurrence-free survival (BCR-FS) between the limited-PLND group (before October 2015, n = 283) and the non-PLND group (after November 2015, n = 233). Read More

View Article and Full-Text PDF

Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy.

Clin Genitourin Cancer 2022 May 18. Epub 2022 May 18.

Urology Unit, Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Surgery, University of Melbourne, Royal Melbourne Hospital, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia. Electronic address:

Background: Disease recurrence is common following prostatectomy in patients with localised prostate cancer with high-risk features. Although androgen deprivation therapy increases the rates of organ-confined disease and negative surgical margins, there is no significant benefit on disease recurrence. Multiple lines of evidence suggest that (Fibroblast Growth Factor/Fibroblast Growth Factor Receptor) FGF/FGFR-signalling is important in supporting prostate epithelial cell survival in hostile conditions, including acute androgen deprivation. Read More

View Article and Full-Text PDF

Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy.

Brachytherapy 2022 May 26. Epub 2022 May 26.

Department of Urology, Nara Medical University, Kashihara, Nara, Japan.

Objectives: To evaluate late genitourinary (GU) and gastrointestinal (GI) toxicities and radiation-induced second primary cancers (RISPCs) in patients who received low-dose-rate brachytherapy (LDR-BT) with or without external beam radiotherapy for prostate cancer.

Methods: This retrospective study included 897 consecutive patients who received LDR-BT between July 2004 and July 2015 in our institution. Adverse events and the incidence of second primary cancers were evaluated at 1, 3, 6, 12, 18, 24, 30, 36, 48, 54, and 60 mo after LDR-BT and then once a year. Read More

View Article and Full-Text PDF

High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.

Prostate Cancer Prostatic Dis 2022 May 14. Epub 2022 May 14.

Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Background: Data on advanced prostate cancer (PCa) suggest more prior systemic therapies might reduce tumor immune responsiveness. In treatment-naïve primary PCa, recent work correlated intratumoral plasma cell content with enhanced tumor immune-responsiveness. We sought to identify features of localized PCa at a high risk of recurrence following local treatment with high plasma cell content to help focus future immune-based neoadjuvant trials. Read More

View Article and Full-Text PDF

Impact of age on treatment response in men with prostate cancer treated with radiotherapy.

BJUI Compass 2022 May 27;3(3):243-250. Epub 2021 Dec 27.

Department of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA.

Objective: To analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer (PCa) treated with radiation therapy.

Subjects And Methods: We identified 12 784 patients with intermediate- or high-risk localized PCa treated with radiation therapy (RT) and neoadjuvant androgen deprivation therapy (ADT) between 2000 and 2015 from nationwide Veterans Affairs data. Patients were grouped into three age categories (≤59, 60-69, and ≥70 years old). Read More

View Article and Full-Text PDF

High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.

Lancet Oncol 2022 05 12;23(5):671-681. Epub 2022 Apr 12.

Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Radiation Oncology Department, Clínical Universitaria de Navarra, Madrid, Spain.

Background: The optimal duration of androgen deprivation combined with high-dose radiotherapy in prostate cancer remains controversial. The DART 01/05 trial was designed to determine whether long-term androgen deprivation is superior to short-term androgen deprivation when combined with high-dose radiotherapy. The 5-year results showed that 2 years of adjuvant androgen deprivation combined with high-dose radiotherapy significantly improved biochemical control, metastasis, and overall survival, especially in patients with high-risk disease. Read More

View Article and Full-Text PDF

Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.

Indian J Cancer 2022 Mar;59(Supplement):S142-S159

Medical Affairs, AstraZeneca Pharma India Ltd, Manyatha Tech Park, Rachenahalli, Bangalore, Karnataka, India, Bangalore.

Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various GnRH-A. All GnRH-A (goserelin, triptorelin, buserelin, histrelin, and leuprorelin) have comparable potential to suppress testosterone (T) levels (≤50 ng/dL in a month and ≤20 ng/dL in 3 months). Read More

View Article and Full-Text PDF

Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer.

J Contemp Brachytherapy 2022 Feb 18;14(1):15-22. Epub 2022 Feb 18.

Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.

Purpose: Serum prostate-specific antigen (PSA) kinetics has been linked to prognosis in prostate cancer (PCa) patients. Our goal was to analyze the association between PSA kinetics and metastasis-free survival (MFS) in patients with localized PCa treated with high-dose-rate (HDR) brachytherapy (BT) boost combined with external beam radiotherapy (EBRT).

Material And Methods: We retrospectively analyzed multiple PSA kinetics related to PSA nadir (nPSA), PSA bouncing, and biochemical recurrence (BCR) in 186 PCa patients treated with neoadjuvant androgen deprivation therapy (ADT), followed by EBRT combined with HDR-BT boost. Read More

View Article and Full-Text PDF
February 2022

Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.

J Urol 2022 07 1;208(1):90-99. Epub 2022 Mar 1.

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, Maryland.

Purpose: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes.

Materials And Methods: The goal of this current study was to evaluate the ability of antibodies against prostate-specific membrane antigen (PSMA) to specifically detect residual tumor in a cohort of 35 patients treated with iADT plus enzalutamide for 6 months prior to radical prostatectomy. Read More

View Article and Full-Text PDF

Impacts of Neoadjuvant Hormonal Therapy Prior to Robot-Assisted Radical Prostatectomy on Postoperative Hormonal- and Sexual-Related Quality of Life - Assessment by Patient-Reported Questionnaire.

Res Rep Urol 2022 19;14:39-48. Epub 2022 Feb 19.

Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Purpose: Neoadjuvant hormonal therapy (HT) before radical prostatectomy (RP) is not recommended by current guidelines in terms of oncological outcomes. Despite this, neoadjuvant HT is sometimes conducted before RP for a small proportion of patients in clinical practice. This study evaluated the impacts of neoadjuvant HT on hormonal- and sexual-related quality of life (QOL) among patients who underwent robot-assisted RP (RARP). Read More

View Article and Full-Text PDF
February 2022

Implications and effects of COVID-19 on diagnosis and management of prostate cancer.

Curr Opin Urol 2022 05 9;32(3):311-317. Epub 2022 Feb 9.

S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

Purpose Of Review: The Coronavirus disease 2019 (COVID-19) pandemic has led to uncertainty on the optimal management for prostate cancer (PCa). This narrative review aims to shed light on the optimal diagnosis and management of patients with or suspected to have PCa.

Recent Findings: Faecal-oral or aerosol transmission is possible during prostate procedures; caution must be in place when performing digital rectal examinations, transrectal ultrasound-guided prostate biopsies and prostate surgeries requiring general anaesthesia. Read More

View Article and Full-Text PDF

Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis.

Scand J Urol 2022 Apr 10;56(2):85-93. Epub 2022 Feb 10.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Purpose: This study aimed to evaluate the efficacy of long-term neoadjuvant androgen-deprivation therapy (ADT) before radical prostatectomy (RP).

Methods: We conducted meta-analyses and network meta-analyses, which included randomized controlled trials that assessed patients with prostate cancer (PC) who received either short-term (<6 months) or long-term (≥6 months) neoadjuvant ADT before RP.

Results: Thirteen articles with 2778 patients were eligible for analysis. Read More

View Article and Full-Text PDF

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.

Prostate Cancer Prostatic Dis 2022 Jan 28. Epub 2022 Jan 28.

Duke-NUS Medical School, Singapore, Singapore.

Objective: Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II investigation of neoadjuvant apalutamide monotherapy and radical prostatectomy (RP) in the treatment of D'Amico intermediate- and high-risk prostate cancer (NCT03124433).

Materials And Methods: Patients with histologically-proven, D'Amico intermediate- to high-risk prostate adenocarcinoma received apalutamide 240 mg once-daily for 12 weeks followed by RP + /-lymphadenectomy. Read More

View Article and Full-Text PDF
January 2022

Intensity-Modulated Radiotherapy with Regional Hyperthermia for High-Risk Localized Prostate Carcinoma.

Cancers (Basel) 2022 Jan 13;14(2). Epub 2022 Jan 13.

Department of Urology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.

Background: The purpose of this study was to evaluate the efficacy and toxicity of adding regional hyperthermia to intensity-modulated radiotherapy (IMRT) plus neoadjuvant androgen deprivation therapy (ADT) for high-risk localized prostate carcinoma.

Methods: Data from 121 consecutive patients with high-risk prostate carcinoma who were treated with IMRT were retrospectively analyzed. The total planned dose of IMRT was 76 Gy in 38 fractions for all patients; hyperthermia was used in 70 of 121 patients. Read More

View Article and Full-Text PDF
January 2022

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.

Lancet Oncol 2022 02 17;23(2):304-316. Epub 2022 Jan 17.

Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.

Background: Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer. This individual patient data meta-analysis of relevant randomised trials aimed to quantify the benefit of these interventions in aggregate and in clinically relevant subgroups.

Methods: For this meta-analysis, we performed a systematic literature search in MEDLINE, Embase, trial registries, the Web of Science, Scopus, and conference proceedings to identify trials with results published in English between Jan 1, 1962, and Dec 30, 2020. Read More

View Article and Full-Text PDF
February 2022

Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer.

Clin Oncol (R Coll Radiol) 2022 06 13;34(6):e246-e253. Epub 2022 Jan 13.

Mount Vernon Cancer Centre, Northwood, Middlesex, UK; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.

Aims: The benefits of neoadjuvant androgen deprivation therapy (nADT) in the management of intermediate- and high-risk prostate cancer patients have been well-established. The aim of this study was to identify radiomic prognostic features derived from routine anatomic magnetic resonance imaging (MRI) sequences that can predict the response of the prostate cancer to nADT.

Materials And Methods: Patients with intermediate- and high-risk prostate cancer (with one of clinical stage ≥ T2c, Gleason score ≥7 or presenting prostate-specific antigen ≥10) who received 3 months of ADT prior to radical external beam radiotherapy were enrolled into this study. Read More

View Article and Full-Text PDF

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer.

Cancers (Basel) 2021 Dec 29;14(1). Epub 2021 Dec 29.

Department of Surgery, University of Melbourne, Parkville, VIC 3050, Australia.

Prostate cancer (PCa) is a hormone driven cancer, characterised by defects in androgen receptor signalling which drive the disease process. As such, androgen targeted therapies have been the mainstay for PCa treatment for over 70 years. High-risk PCa presents unique therapeutic challenges, namely in minimising the primary tumour, and eliminating any undetected micro metastases. Read More

View Article and Full-Text PDF
December 2021

Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial.

Int J Radiat Oncol Biol Phys 2022 03 14;112(4):880-889. Epub 2021 Nov 14.

The Ottawa Hospital Cancer Centre, University of Ottawa. Electronic address:

Purpose: Both oncologic outcomes and patient-reported outcomes are pivotal in prostate cancer (PCa). However, it remains unknown if there is any association between these 2 outcomes. In this secondary analysis of a randomized controlled trial, we investigated the association of short-term changes in patient-reported outcome with long-term event-free survival (EFS) and metastasis-free survival (MFS) in localized PCa. Read More

View Article and Full-Text PDF

Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.

Int J Urol 2022 Feb 11;29(2):143-151. Epub 2021 Nov 11.

Departments of, Urology, Nara Medical University, Kashihara, Nara, Japan.

Objective: Higher quality of postimplant dosimetric evaluation is associated with higher biochemical recurrence-free survival rates after low-dose-rate brachytherapy for localized prostate cancer. Postimplant prostate D90 is a key dosimetric parameter showing the quality of low-dose-rate brachytherapy. In this study, to improve the quality of low-dose-rate brachytherapy for localized prostate cancer, we investigated pre-implant factors affecting the reduction of postimplant prostate D90. Read More

View Article and Full-Text PDF
February 2022

Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.

Radiat Oncol 2021 Nov 4;16(1):212. Epub 2021 Nov 4.

Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.

Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these changes. This planned interim analysis reports the gastrointestinal and genitourinary toxicity profiles of PCa patients receiving ADT and prostate/pelvic radiotherapy plus metformin versus placebo as part of a phase 2 randomized controlled trial. Read More

View Article and Full-Text PDF
November 2021

Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer.

Clin Oncol (R Coll Radiol) 2022 01 30;34(1):e61-e68. Epub 2021 Oct 30.

The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Department of Radiology, Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:

Aims: Although health-related quality of life (HR-QoL) outcomes are pivotal in oncology, the prognostic significance of patient-reported HR-QoL metrics is largely undefined in localised prostate cancer. We report the association of baseline HR-QoL metrics with overall survival and toxicity in localised prostate cancer.

Materials And Methods: This was a secondary analysis of a phase III randomised controlled study conducted in a single-payer health system. Read More

View Article and Full-Text PDF
January 2022

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer.

Adv Radiat Oncol 2021 Nov-Dec;6(6):100803. Epub 2021 Sep 10.

Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.

Purpose: Treatment with long-term androgen deprivation therapy (ADT) and radiation therapy (RT) is the nonsurgical standard-of-care for patients with high- or very high-risk prostate cancer (HR-PC), but the optimal timing between ADT and RT initiation is unknown. We evaluate the influence of timing between ADT and RT on outcomes in patients with HR-PC using a large national cancer database.

Methods And Materials: Data for patients with clinical T1-T4 N0, M0, National Cancer Comprehensive Network HR-PC who were treated with definitive external RT (≥60 Gy) and ADT starting either before or within 14 days after RT start were extracted from the National Cancer Database (2004-2015). Read More

View Article and Full-Text PDF
September 2021

Practice Patterns of Korean Urologists Regarding Positive Surgical Margins after Radical Prostatectomy: a Survey and Narrative Review.

J Korean Med Sci 2021 Oct 25;36(41):e256. Epub 2021 Oct 25.

Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.

Background: There is no clear consensus on the optimal treatment with curative intent for patients with positive surgical margins (PSMs) following radical prostatectomy (RP). The aim of this study was to investigate the perceptions and treatment patterns of Korean urologists regarding the resection margin after RP.

Methods: A preliminary questionnaire was prepared by analyzing various studies on resection margins after RP. Read More

View Article and Full-Text PDF
October 2021

Early toxicities of ultrahypofractionated stereotactic body radiotherapy for intermediate risk localized prostate cancer using cone-beam computed tomography and real-time three-dimensional transperineal ultrasound monitoring.

Radiat Oncol J 2021 Sep 28;39(3):239-245. Epub 2021 Sep 28.

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong.

Purpose: Image-guided radiotherapy (IGRT) is central to the safe and effective delivery of ultrahypofractionated (UF) stereotactic body radiotherapy (SBRT) for localized prostate cancer. However, the optimal IGRT modality remains uncertain. We aim to study the safety of performing UF-SBRT using cone-beam computed tomography (CBCT) and real-time transperineal ultrasound (TPUS) monitoring. Read More

View Article and Full-Text PDF
September 2021

Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.

Nat Rev Urol 2021 12 15;18(12):739-762. Epub 2021 Sep 15.

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Patients with high-risk prostate cancer treated with curative intent are at an increased risk of biochemical recurrence, metastatic progression and cancer-related death compared with patients treated for low-risk or intermediate-risk disease. Thus, these patients often need multimodal therapy to achieve complete disease control. Over the past two decades, multiple studies on the use of neoadjuvant treatment have been performed using conventional androgen deprivation therapy, which comprises luteinizing hormone-releasing hormone agonists or antagonists and/or first-line anti-androgens. Read More

View Article and Full-Text PDF
December 2021

Membrane translocation and activation of GnRH receptor sensitize prostate cancer cells to radiation.

Int J Radiat Biol 2021 27;97(11):1555-1562. Epub 2021 Sep 27.

Departamento de Oncología Básica y Clínica, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Background: GnRH analogs are widely used as neoadjuvant agents for radiotherapy in prostate cancer (PCa) patients, with well-documented effects in reducing tumor bulk and increasing progression-free survival. GnRH analogs act locally in the prostate by triggering apoptosis of PCa cells via activation of the GnRH receptor (GnRHR). During PCa progression, the distribution of GnRHR within the cell is altered, with reduced expression in the cell membrane and remaining sequestered in the endoplasmic reticulum. Read More

View Article and Full-Text PDF
January 2022

Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.

Andrology 2022 02 24;10(2):270-278. Epub 2021 Sep 24.

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Background: Pharmacobiological behavior differs between gonadotropin-releasing hormone (GnRH) antagonists and GnRH agonists. However, reliable evidence clarifying the difference between them is limited.

Objectives: We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer. Read More

View Article and Full-Text PDF
February 2022

Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration.

Urol Oncol 2022 02 26;40(2):59.e7-59.e12. Epub 2021 Aug 26.

Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.

Objective: To determine the feasibility and outcome of radical prostatectomy (RP) following neoadjuvant therapy (NAT) in patients with initial inoperable, rectum-infiltrating cT4 prostate cancer (PCa).

Methods: From 01/2018 to 12/2020, 26 patients with clinical (DRE) or radiographical (mpMRI) suspicion of rectum infiltrating PCa at diagnosis and NAT prior to RP were retrospectively identified from our prospective institutional database. Two patients were still inoperable after NAT. Read More

View Article and Full-Text PDF
February 2022

Radiation therapy with curative intention in men with metastatic prostate carcinoma: shoot'em all!

Rep Pract Oncol Radiother 2021 12;26(4):605-615. Epub 2021 Aug 12.

Department of Radiation Oncology, HM Hospitales, Madrid, Spain.

Background: About 5% of prostate cancer cases are metastatic at diagnoses. Radiotherapy of both primary tumor and secondary lesions can be, in addition to systemic treatments, a radical alternative for selected patients.

Materials And Methods: Patients with de novo prostate carcinoma with bone or lymph node metastases were retrospectively reviewed. Read More

View Article and Full-Text PDF